Immunocore Set to Shine at Upcoming Investor Conferences
Immunocore Holdings plc (Nasdaq: IMCR), a pioneering biotechnology firm specializing in revolutionary immunomodulating medicines, has announced its participation in several prominent investor conferences. This series of events is scheduled for November, where the company aims to engage with investors and showcase its transformative approaches in treating serious health conditions, including cancer, and various infectious and autoimmune diseases.
Details on Investor Conferences
Immunocore's management will be actively involved in two major conferences. The first is the Guggenheim Securities Healthcare Innovation Conference, where a fireside chat is set for the 12th of November at 1:00 p.m. EST. Subsequently, Immunocore will also participate in the Jefferies London Healthcare Conference on the 21st of November, with a discussion at 9:00 a.m. GMT. These sessions provide a valuable platform for the company to highlight its progress and developments in the biotechnology space.
Webcast Presentation Access
The presentations at these conferences will be accessible via live webcasts. Interested parties can catch the discussions by visiting the 'Events & Presentations' section in the Investors area of Immunocore's official website. For those unable to attend live, replays of the presentations will be available for a limited time afterwards, ensuring that all interested stakeholders can stay informed.
Introducing Immunocore's Cutting-Edge Approach
Immunocore stands out in the biotechnology domain as a company innovating in the field of T-cell therapy. They have developed the ImmTAX platform, which facilitates the creation of a unique class of TCR bispecific immunotherapies. This versatile approach is geared toward addressing a wide array of diseases. The company currently boasts a strong pipeline of five clinical programs focused on oncology and various infectious diseases, alongside advanced pre-clinical studies targeting autoimmune disorders.
Highlighting KIMMTRAK
The flagship therapeutic from Immunocore, KIMMTRAK, has made significant strides and received approval for treating patients that are HLA-A*02:01-positive with unresectable or metastatic uveal melanoma across several major markets, including the U.S., Canada, and locations within the European Union. This innovation represents a crucial advancement in treatment options available for some of the most challenging cases of cancer.
Aiming for a Broader Impact
With the unwavering commitment to advancing patient care, Immunocore remains focused on developing therapies that can drastically improve patient outcomes. The company’s comprehensive approach not only reflects a strong pipeline but also demonstrates its dedication to scientific excellence and patient-focused healthcare solutions.
Contact and Investor Relations
For additional information, Immunocore encourages interested parties to reach out. Sébastien Desprez leads the communications team, and prospective investors can also connect with Clayton Robertson, the head of Investor Relations, for insights regarding investment opportunities.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
Frequently Asked Questions
What is the purpose of the investor conferences?
The conferences aim to provide a platform for Immunocore to engage with investors, provide updates on their innovative therapies, and foster relationships with stakeholders.
When will Immunocore participate in the conferences?
Immunocore will participate in the Guggenheim Securities Conference on November 12, 2024, and the Jefferies London Conference on November 21, 2024.
How can investors access the conference presentations?
Investors can access the live webcasts of the presentations on Immunocore's official website under the 'Events & Presentations' section.
What innovative treatments does Immunocore focus on?
Immunocore specializes in TCR bispecific immunotherapies aimed at treating cancer and various autoimmune and infectious diseases.
Who should investors contact for more information?
Investors can contact Clayton Robertson, Head of Investor Relations, or Sébastien Desprez, Head of Communications, for further information.
